These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Treatment of heart failure with spironolactone--trial and tribulations. McMurray JJ; O'Meara E N Engl J Med; 2004 Aug; 351(6):526-8. PubMed ID: 15295043 [No Abstract] [Full Text] [Related]
7. Study warns of danger of combining spironolactone and ACE inhibitors in heart patients. Gottlieb S BMJ; 2004 Aug; 329(7463):420. PubMed ID: 15321896 [No Abstract] [Full Text] [Related]
8. Worsening of motor symptoms and gynecomastia during spironolactone treatment in a patient with Parkinson's disease and congestive heart failure. Teive HA; Munhoz RP; Werneck LC Mov Disord; 2007 Aug; 22(11):1678-9. PubMed ID: 17534964 [No Abstract] [Full Text] [Related]
9. Hyperkalemia after the publication of RALES. Newsome BB; Warnock DG N Engl J Med; 2004 Dec; 351(23):2448-50; author reply 2448-50. PubMed ID: 15580678 [No Abstract] [Full Text] [Related]
10. Hyperkalemia after the publication of RALES. Cavallari L; Vaitkus P; Groo V N Engl J Med; 2004 Dec; 351(23):2448-50; author reply 2448-50. PubMed ID: 15580677 [No Abstract] [Full Text] [Related]
11. Use of spironolactone in dermatology. Rathnayake D; Sinclair R Skinmed; 2010; 8(6):328-32; quiz 333. PubMed ID: 21413648 [TBL] [Abstract][Full Text] [Related]
12. Use of antagonists of aldosterone in patients with chronic kidney disease: Potential advantages and risks. Campese VM; Park J J Hypertens; 2006 Nov; 24(11):2157-9. PubMed ID: 17053534 [No Abstract] [Full Text] [Related]
13. Hyperkalemia after the publication of RALES. Witham MD; Gillespie ND; Struthers AD N Engl J Med; 2004 Dec; 351(23):2448-50; author reply 2448-50. PubMed ID: 15580679 [No Abstract] [Full Text] [Related]
14. New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia. Cruz CS; Cruz LS; Domingues GS; Souza CA Expert Opin Drug Saf; 2005 Jul; 4(4):677-88. PubMed ID: 16011447 [TBL] [Abstract][Full Text] [Related]
15. Hyperkalemia after the publication of RALES. Goldfarb DS N Engl J Med; 2004 Dec; 351(23):2448-50; author reply 2448-50. PubMed ID: 15575065 [No Abstract] [Full Text] [Related]
16. Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message. Witham MD; Gillespie ND; Struthers AD Br J Clin Pharmacol; 2004 Nov; 58(5):554-7. PubMed ID: 15521905 [TBL] [Abstract][Full Text] [Related]
17. Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism. Poggio R; Grancelli HO; Miriuka SG Postgrad Med J; 2010 Mar; 86(1013):136-42. PubMed ID: 20237007 [TBL] [Abstract][Full Text] [Related]
18. [Old man with bosom]. Winter M MMW Fortschr Med; 2006 Jun; 148(26):61. PubMed ID: 16875387 [No Abstract] [Full Text] [Related]
19. Slow adoption of helpful heart failure drug. Many people who could benefit from spironolactone aren't getting it. Harv Heart Lett; 2010 Feb; 20(6):2. PubMed ID: 20376944 [No Abstract] [Full Text] [Related]